[1] |
马杰科, 幸兵, 王任直, 等. 表现为动眼神经麻痹的垂体腺瘤卒中的诊治(附15例分析) [J]. 中华神经外科疾病研究杂志, 2014, 13(2): 105-109. |
[2] |
谭惠文, 李丹婷, 余叶蓉. 垂体催乳素瘤的临床特点及诊治要点更新——基于《2022版ICCE/AME垂体催乳素瘤临床实践共识》解读[J]. 中国全科医学, 2024, 27(6): 650-655. |
[3] |
葛均波, 徐永健, 王辰. 内科学[M]. 北京: 人民卫生出版社, 2018. |
[4] |
Petersenn, S., Fleseriu, M., Casanueva, F.F., Giustina, A., Biermasz, N., Biller, B.M.K., et al. (2023) Diagnosis and Management of Prolactin-Secreting Pituitary Adenomas: A Pituitary Society International Consensus Statement. Nature Reviews Endocrinology, 19, 722-740. https://doi.org/10.1038/s41574-023-00886-5 |
[5] |
Melmed, S. (2020) Pituitary-Tumor Endocrinopathies. New England Journal of Medicine, 382, 937-950. https://doi.org/10.1056/nejmra1810772 |
[6] |
Melmed, S., Kaiser, U.B., Lopes, M.B., Bertherat, J., Syro, L.V., Raverot, G., et al. (2022) Clinical Biology of the Pituitary Adenoma. Endocrine Reviews, 43, 1003-1037. https://doi.org/10.1210/endrev/bnac010 |
[7] |
中国垂体腺瘤协作组. 中国垂体腺瘤外科治疗专家共识[J]. 中华医学杂志, 2015, 95(5): 324-329. |
[8] |
Gillam, M.P., Molitch, M.E., Lombardi, G. and Colao, A. (2006) Advances in the Treatment of Prolactinomas. Endocrine Reviews, 27, 485-534. https://doi.org/10.1210/er.2005-9998 |
[9] |
Tritos, N.A. and Miller, K.K. (2023) Diagnosis and Management of Pituitary Adenomas. JAMA, 329, 1386-1398. https://doi.org/10.1001/jama.2023.5444 |
[10] |
Lisa, B., Arno, V., Christophe, D.B., Heyning Paul, V.d. and Carlien, D.H. (2023) Giant Prolactinomas, a Detailed Analysis of 196 Adult Cases. Pituitary, 26, 529-537. https://doi.org/10.1007/s11102-023-01337-0 |
[11] |
张媛, 魏世辉, 郝继龙. 垂体腺瘤200例眼部表现与MRI特点的相关性分析[J]. 国际眼科杂志, 2007, 7(4): 1069-1072. |
[12] |
Kastelan, D. and Korsic, M. (2007) High Prevalence Rate of Pituitary Incidentaloma: Is It Associated with the Age-Related Decline of the Sex Hormones Levels? Medical Hypotheses, 69, 307-309. https://doi.org/10.1016/j.mehy.2006.11.044 |
[13] |
Shimon, I., Bronstein, M.D., Shapiro, J., Tsvetov, G., Benbassat, C. and Barkan, A. (2014) Women with Prolactinomas Presented at the Postmenopausal Period. Endocrine, 47, 889-894. https://doi.org/10.1007/s12020-014-0259-1 |
[14] |
中国垂体腺瘤协作组. 中国垂体催乳素腺瘤诊治共识(2014版) [J]. 中华医学杂志, 2014, 94(31): 2406-2411. |
[15] |
郭庆, 庞燕华. 眼科检查和功能性磁共振在垂体腺瘤研究中的应用进展[J]. 国际眼科杂志, 2022, 22(7): 1148-1152. |
[16] |
周良辅. 现代神经外科学[M]. 第2版. 上海: 复旦大学出版社, 2015. |
[17] |
刘斌, 张艳玲. 动眼神经麻痹的病因分析和诊断进展[J]. 局解手术学杂志, 2010, 19(3): 240-241. |
[18] |
Chen, H., Wang, X., Yao, S., Raza, H.K., Jing, J., Cui, G., et al. (2019) The Aetiologies of Unilateral Oculomotor Nerve Palsy: A Clinical Analysis on 121 Patients. Somatosensory & Motor Research, 36, 102-108. https://doi.org/10.1080/08990220.2019.1609438 |
[19] |
范祖莉, 谭惠文, 余叶蓉, 等. 多巴胺受体激动剂治疗巨大垂体催乳素细胞腺瘤伴垂体卒中1例[J]. 重庆医科大学学报, 2023, 48(9): 1114-1115. |
[20] |
Auriemma, R.S., Pirchio, R., Pivonello, C., Garifalos, F., Colao, A. and Pivonello, R. (2023) Approach to the Patient with Prolactinoma. The Journal of Clinical Endocrinology & Metabolism, 108, 2400-2423. https://doi.org/10.1210/clinem/dgad174 |
[21] |
Iacovazzo, D. and De Marinis, L. (2014) Treatment of Hyperprolactinemia in Post-Menopausal Women: Pros. Endocrine, 48, 76-78. https://doi.org/10.1007/s12020-014-0377-9 |
[22] |
于群, 鲁艾林. 垂体腺瘤分类及治疗方法的研究进展[J]. 中国肿瘤外科杂志, 2018, 10(1): 60-63. |
[23] |
Pekić, S., Medic Stojanoska, M. and Popovic, V. (2018) Hyperprolactinemia/Prolactinomas in the Postmenopausal Period: Challenges in Diagnosis and Management. Neuroendocrinology, 109, 28-33. https://doi.org/10.1159/000494725 |
[24] |
李仁涛. 垂体腺瘤相关动眼神经麻痹发生及预后的影响因素分析[D]: [硕士学位论文]. 济南: 山东大学, 2023. |
[25] |
Cozzi, R., Ambrosio, M.R., Attanasio, R., Battista, C., Bozzao, A., Caputo, M., et al. (2022) Italian Association of Clinical Endocrinologists (AME) and International Chapter of Clinical Endocrinology (ICCE). Position Statement for Clinical Practice: Prolactin-Secreting Tumors. European Journal of Endocrinology, 186, 1-33. https://doi.org/10.1530/eje-21-0977 |